Trial Profile
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 Jan 2023 Primary endpoint has been met, (Overall survival (OS) as per Results presented at the 2023 Gastrointestinal Cancers Symposium
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium
- 17 Nov 2022 Planned End Date changed from 1 Jun 2025 to 1 Jul 2027.